Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 6/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336661 | 1.00 | MMP12 (0.51) | MMP12CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL299079 | 0.86 | MMP12 (0.65) | MMP12PDE3BPDE3APARP1CMA1 | |
| SCHEMBL29452973 | 0.86 | MMP12 (0.65) | MMP12PDE3BPDE3APARP1CMA1 | |
| SCHEMBL24720317 | 0.83 | CMA1 (0.45) | CYP11B1CYP11B2PDE3BPDE3ACMA1 | |
| SCHEMBL30053776 | 0.79 | NR3C2 (0.57) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL3594625 | 0.79 | MMP12 (0.51) | MMP12CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL1861248 | 0.79 | NR3C2 (0.57) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL30799148 | 0.79 | MMP12 (0.51) | MMP12CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL276741 | 0.79 | MMP12 (0.51) | MMP12CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL304249 | 0.79 | DRD4 (0.56) | MMP12CYP11B1CYP11B2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4696688-A1 | BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340529-A1 | Heterocyclic Compounds as Immunomodulators of PD-L1 Interactions | ASCLETIS BIOSCIENCE CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| WO-2025201477-A1 | SPIROCYCLIC GSDME INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO.,LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| EP-4624464-A1 | PYRIDINE POLYCYCLIC COMPOUND INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| EP-1196412-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6716841-B2 | SUCH AS 1-((1-(3-(AMINOMETHYL)PHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-5-YL)CARBONYL) -5-(2-( AMINOSULFONYL)PHENYL)-2,3-DIHYDRO-1H-INDOLE FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS; ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-20030096820-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2003-05-22 | — | — | US | disclosed |
| US-6534535-B1 | Administering indole derivative as anticoagulant | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| WO-2001012600-A9 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6429205-B1 | ANTICOAGULANTS | BRISTOL-MEYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | disclosed |
| WO-2001012600-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096820-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | SERPINC1, CTRB1, F2 | MMP12 679/4885CYP11B1 1202/4885CYP11B2 2168/4885 |
| US-20250340529-A1 | Heterocyclic Compounds as Immunomodulators of PD-L1 Interactions | CD274, PDCD1LG2, PDCD1 | MMP12 707/4885CYP11B1 1746/4885CYP11B2 1568/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MMP12 1820/4885CYP11B1 192/4885CYP11B2 93/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | MMP12 2677/4885CYP11B1 2743/4885CYP11B2 2880/4885 |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | MMP12 1/4885CYP11B1 565/4885CYP11B2 675/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | MMP12 4148/4885CYP11B1 68/4885CYP11B2 86/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | MMP12 1036/4885CYP11B1 4229/4885CYP11B2 4345/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | MMP12 3729/4885CYP11B1 104/4885CYP11B2 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.